News and Topics
Featured News
Public engagement is key to building momentum for longevity science, and you can make a real difference. Our nonprofit team works hard to bring you the latest news in the field. Please consider making a donation to support our work. Thank You.
Most cardiovascular trials focus on lowering LDL cholesterol or reducing inflammation to slow disease progression. UDP-003 targets the root cause: toxic
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove
This month, a group of researchers published an annual report on the clinical trials that are testing drugs for Alzheimer’s disease.
We are super excited to share with you that today we released AI4L – “AI for Practical Longevity”, an open-source system
A new study suggests that GLP-1 receptor agonists do not affect muscle mass any more than weight loss caused by caloric
Dr. Junyue Cao is a professor at the Rockefeller University, and his lab develops ultra-high-throughput single-cell technologies and applies them to
In Aging Cell, researchers have elucidated the relationship between intestinal aging and age-related changes to the gut microbiome. Two interdependent biologies
In a new study, the popular supplement creatine seemed to add to some of the beneficial effects of power training [1].
A new study has pit an advanced large language model against human physicians in tasks involving complex reasoning, treatment recommendations, and
The Longevity Investor Network (LIN) was created to help bridge the gap between promising longevity startups and the investors capable of
Aging is a multifaceted topic, and it’s becoming more and more clear that the only way to deal with it is
A perspective published in Aging Cell details the replacement-based approaches being investigated by several research organizations. Repair versus replacement This perspective
A recent study found an association between longer and more frequent daytime napping and higher mortality risk. The authors suggest using
A new study calls for caution in using the well-known senolytic treatment of dasatinib and quercetin (D+Q), showing that it causes